References
- Addie, M., Ballard, P., Buttar, D., Crafter, C., Currie, G., Davies, B. R., Debreczeni, J., Dry, H., Dudley, P., Greenwood, R., Johnson, P. D., Kettle, J. G., Lane, C., Lamont, G., Leach, A., Luke, R. W. A., Morris, J., Ogilvie, D., Page, K., … Ruston, L. (2013). Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases. Journal of Medicinal Chemistry, 56(5), 2059–2073. https://doi.org/https://doi.org/10.1021/jm301762v
- Archewa, P., Pata, S., Chotjumlong, P., Supanchart, C., Krisanaprakornkit, S., & Iamaroon, A. (2017). Akt2 and p-Akt overexpression in oral cancer cells is due to a reduced rate of protein degradation. Journal of Investigative and Clinical Dentistry, 8(1), e12194. https://doi.org/https://doi.org/10.1111/jicd.12194
- Ashburn, T. T., & Thor, K. B. (2004). Drug repositioning: Identifying and developing new uses for existing drugs. Nature Reviews. Drug Discovery, 3(8), 673–683. https://doi.org/https://doi.org/10.1038/nrd1468
- Ashour, M., Youssef, F., Gad, H., & Wink, M. (2017). Inhibition of cytochrome P450 (CYP3A4) activity by extracts from 57 plants used in traditional Chinese medicine (TCM). Pharmacognosy Magazine, 13(50), 300–308. https://doi.org/https://doi.org/10.4103/0973-1296.204561
- Berjanskii, M., Liang, Y., Zhou, J., Tang, P., Stothard, P., Zhou, Y., Cruz, J., MacDonell, C., Lin, G., Lu, P., & Wishart, D. S. (2010). PROSESS: A protein structure evaluation suite and server. Nucleic Acids Research, 38(Web Server), W633–W640. https://doi.org/https://doi.org/10.1093/nar/gkq375
- Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., Shindyalov, I. N., & Bourne, P. E. (2000). The Protein Data Bank. Nucleic Acids Research, 28(1), 235–242. https://doi.org/https://doi.org/10.1093/nar/28.1.235
- Binda, C., Hubálek, F., Li, M., Herzig, Y., Sterling, J., Edmondson, D. E., & Mattevi, A. (2004). Crystal structures of monoamine oxidase B in complex with four inhibitors of the N-propargylaminoindan class. Journal of Medicinal Chemistry, 47(7), 1767–1774. https://doi.org/https://doi.org/10.1021/jm031087c
- Binda, C., Hubálek, F., Li, M., Herzig, Y., Sterling, J., Edmondson, D. E., & Mattevi, A. (2005). Binding of rasagiline-related inhibitors to human monoamine oxidases: A kinetic and crystallographic analysis. Journal of Medicinal Chemistry, 48(26), 8148–8154. https://doi.org/https://doi.org/10.1021/jm0506266
- Biovia, D. S., Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., & Richmond, T. J. (2000). Dassault Systèmes BIOVIA, Discovery Studio Visualizer, v.17.2, San Diego: Dassault Systèmes, 2016. The Journal of Chemical Physics, 10, 21–9991. https://doi.org/https://doi.org/10.1016/0021-9991(74)90010-2
- Carrascoza, F., Zaric, S., & Silaghi-Dumitrescu, R. (2014). Computational study of protein secondary structure elements: Ramachandran plots revisited. Journal of Molecular Graphics & Modelling, 50, 125–133. https://doi.org/https://doi.org/10.1016/j.jmgm.2014.04.001
- Catalogna, G., Talarico, C., Dattilo, V., Gangemi, V., Calabria, F., D'Antona, L., Schenone, S., Musumeci, F., Bianco, C., Perrotti, N., Amato, R., & Cascini, G. L. (2017). The SGK1 kinase inhibitor SI113 sensitizes theranostic effects of the 64CuCl2 in human glioblastoma multiforme cells. Cellular Physiology and Biochemistry: International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology, 43(1), 108–119. https://doi.org/https://doi.org/10.1159/000480328
- Chen, Y. C. (2015). Beware of docking! Trends in Pharmacological Sciences, 36(2), 78–95. https://doi.org/https://doi.org/10.1016/j.tips.2014.12.001
- D’Antona, L., Dattilo, V., Catalogna, G., Scumaci, D., Fiumara, C. V., Musumeci, F., Perrotti, G., Schenone, S., Tallerico, R., Spoleti, C. B., Costa, N., Iuliano, R., Cuda, G., Amato, R., & Perrotti, N. (2019). In preclinical model of ovarian cancer, the SGK1 inhibitor SI113 counteracts the development of paclitaxel resistance and restores drug sensitivity. Translational Oncology, 12(8), 1045–1055. https://doi.org/https://doi.org/10.1016/j.tranon.2019.05.008
- Davies, B. R., Greenwood, H., Dudley, P., Crafter, C., Yu, D.-H., Zhang, J., Li, J., Gao, B., Ji, Q., Maynard, J., Ricketts, S.-A., Cross, D., Cosulich, S., Chresta, C. C., Page, K., Yates, J., Lane, C., Watson, R., Luke, R., Ogilvie, D., & Pass, M. (2012). Preclinical pharmacology of AZD5363, an inhibitor of AKT: Pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Molecular Cancer Therapeutics, 11(4), 873–887. https://doi.org/https://doi.org/10.1158/1535-7163.MCT-11-0824-T
- Davies, M. A. (2011). Regulation, role, and targeting of Akt in cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 29(35), 4715–4717. https://doi.org/https://doi.org/10.1200/JCO.2011.37.4751
- Davies, T. G., Verdonk, M. L., Graham, B., Saalau-Bethell, S., Hamlett, C. C. F., McHardy, T., Collins, I., Garrett, M. D., Workman, P., Woodhead, S. J., Jhoti, H., & Barford, D. (2007). A structural comparison of inhibitor binding to PKB, PKA and PKA-PKB chimera. Journal of Molecular Biology, 367(3), 882–894. https://doi.org/https://doi.org/10.1016/j.jmb.2007.01.004
- DeLano, W. L. (2002). PyMOL: An open-source molecular graphics tool. CCP4 Newsletter on Protein Crystallography, 40, 82–92. https://doi.org/https://doi.org/10.1038/s41598-017-03842-2
- Dougherty, D. A. (2013). The cation-π interaction. Accounts of Chemical Research, 46(4), 885–893. https://doi.org/https://doi.org/10.1021/ar300265y
- Dummler, B., & Hemmings, B. A. (2007). Physiological roles of PKB/Akt isoforms in development and disease. Biochemical Society Transactions, 35(Pt 2), 231–235. https://doi.org/https://doi.org/10.1042/BST0350231
- Gharat, S. A., Momin, M., & Bhavsar, C. (2016). Oral squamous cell carcinoma: Current treatment strategies and nanotechnology-based approaches for prevention and therapy. Critical Reviews in Therapeutic Drug Carrier Systems, 33(4), 363–400. https://doi.org/https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2016016272
- Gillison, M. L. (2007). Current topics in the epidemiology of oral cavity and oropharyngeal cancers. Head & Neck, 29(8), 779–792. https://doi.org/https://doi.org/10.1002/hed.20573
- Hers, I., Vincent, E. E., & Tavaré, J. M. (2011). Akt signalling in health and disease. Cellular Signalling, 23(10), 1515–1527. https://doi.org/https://doi.org/10.1016/j.cellsig.2011.05.004
- Iamaroon, A., & Krisanaprakornkit, S. (2009). Overexpression and activation of Akt2 protein in oral squamous cell carcinoma. Oral Oncology, 45(10), e175–e179. https://doi.org/https://doi.org/10.1016/j.oraloncology.2009.06.003
- Janku, F., Yap, T. A., & Meric-Bernstam, F. (2018). Targeting the PI3K pathway in cancer: Are we making headway? Nature Reviews. Clinical Oncology, 15(5), 273–291. https://doi.org/https://doi.org/10.1038/nrclinonc.2018.28
- Kabir, E. R., Siam, M. K. S., & Mustafa, N. (2019). Scaffold of N-(2-(2-(tosylcarbamoyl)hydrazinyl)ethyl)isonicotinamidereveals anticancer effects through selective inhibition of FAP [Paper presentation]. CSBio ’19: Proceedings of the Tenth International Conference on Computational Systems-Biology and Bioinformatics. Association for Computing Machinery, New York, NY, USA. https://doi.org/https://doi.org/10.1145/3365953.3365963
- Kabir, E. R., Siam, M. K. S., Mustafa, N., & Kabir, S. M. (2018). Molecular docking reveals pitavastatin and related molecules antagonize 1DHF and its pseudogene DHFR2 in cancer treatment [Paper presentation]. ACM International Conference Proceeding Series (pp. 1–9). https://doi.org/https://doi.org/10.1145/3291757.3291763
- Kabir, E. R., Siam, M. K. S., Kabir, S. M., Khan, A., & Rajib, S. A. (2017). Drug repurposing: Targeting mTOR inhibitors for anticancer activity [Paper presentation]. ACM International Conference Proceeding Series (pp. 68–75). Association for Computing Machinery. https://doi.org/https://doi.org/10.1145/3156346.3156359
- Ketabat, F., Pundir, M., Mohabatpour, F., Lobanova, L., Koutsopoulos, S., Hadjiiski, L., Chen, X., Papagerakis, P., & Papagerakis, S. (2019). Controlled drug delivery systems for oral cancer treatment—current status and future perspectives. Pharmaceutics, 11(7), 1–29. https://doi.org/https://doi.org/10.3390/pharmaceutics11070302
- Kukić, P., & Nielsen, J. E. (2010). Electrostatics in proteins and protein-ligand complexes. Future Medicinal Chemistry, 2(4), 647–666. https://doi.org/https://doi.org/10.4155/fmc.10.6
- Kumar, R., Sharma, A., & Tiwari, R. K. (2013). Can we predict blood brain barrier permeability of ligands using computational approaches? Interdisciplinary Sciences, Computational Life Sciences, 5(2), 95–101. https://doi.org/https://doi.org/10.1007/s12539-013-0158-9
- Li, Q., Cheng, T., Wang, Y., & Bryant, S. H. (2010). PubChem as a public resource for drug discovery. Drug Discovery Today, 15(23–24), 1052–1057. https://doi.org/https://doi.org/10.1016/j.drudis.2010.10.003
- Lim, J., Kim, J., Paeng, J., Kim, M., Hong, S., Lee, J., & Hong, S. (2005). Prognostic value of activated Akt expression in oral squamous cell carcinoma. Journal of Clinical Pathology, 58(11), 1199–1205. https://doi.org/https://doi.org/10.1136/jcp.2004.024786
- Lynch, T., & Price, A. (2007). The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. American Family Physician, 76(3), 391–396.
- Markopoulos, A. K. (2012). Current aspects on oral squamous cell carcinoma. The Open Dentistry Journal, 6(1), 126–130. https://doi.org/https://doi.org/10.2174/1874210601206010126
- Marocchio, L. S., Lima, J., Sperandio, F. F., Corrêa, L., & de Sousa, S. O. (2010). Oral squamous cell carcinoma: An analysis of 1,564 cases showing advances in early detection. Journal of Oral Science, 52(2), 267–273. https://doi.org/https://doi.org/10.2334/josnusd.52.267
- Matsumoto, T., Kaifuchi, N., Mizuhara, Y., Warabi, E., & Watanabe, J. (2018). Use of a Caco-2 permeability assay to evaluate the effects of several Kampo medicines on the drug transporter P-glycoprotein. Journal of Natural Medicines, 72(4), 897–904. https://doi.org/https://doi.org/10.1007/s11418-018-1222-x
- Mouth, pharynx & larynx cancer statistics & World Cancer Research Fund. (n.d.). Retrieved October 29, 2019, from https://www.wcrf.org/dietandcancer/cancer-trends/mouth-pharynx-larynx-cancer-statistics
- Nakashiro, K.-I., Tanaka, H., Goda, H., Iwamoto, K., Tokuzen, N., Hara, S., Onodera, J., Fujimoto, I., Hino, S., & Hamakawa, H. (2015). Identification of Akt1 as a potent therapeutic target for oral squamous cell carcinoma. International Journal of Oncology, 47(4), 1273–1281. https://doi.org/https://doi.org/10.3892/ijo.2015.3134
- Nicholson, K. M., & Anderson, N. G. (2002). The protein kinase B/Akt signalling pathway in human malignancy. Cellular Signalling, 14(5), 381–395. https://doi.org/https://doi.org/10.1016/S0898-6568(01)00271-6
- O’Boyle, N. M., Banck, M., James, C. A., Morley, C., Vandermeersch, T., & Hutchison, G. R. (2011). Open Babel: An open chemical toolbox. Journal of Cheminformatics, 3, 33–14. https://doi.org/https://doi.org/10.1186/1758-2946-3-33
- Okuzumi, T., Fiedler, D., Zhang, C., Gray, D. C., Aizenstein, B., Hoffman, R., & Shokat, K. M. (2009). Inhibitor hijacking of akt activation. Nature Chemical Biology, 5(7), 484–493. https://doi.org/https://doi.org/10.1038/nchembio.183
- Panchapakesan, U., & Pollock, C. (2018). Drug repurposing in kidney disease. Kidney International, 94(1), 40–48. https://doi.org/https://doi.org/10.1016/j.kint.2017.12.026
- Pantsar, T., & Poso, A. (2018). Binding affinity via docking: Fact and fiction. Molecules (Molecules), 23(8), 1899–1811. https://doi.org/https://doi.org/10.3390/molecules23081899
- Patil, R., Das, S., Stanley, A., Yadav, L., Sudhakar, A., & Varma, A. K. (2010). Optimized hydrophobic interactions and hydrogen bonding at the target-ligand interface leads the pathways of drug-designing. PloS One, 5(8), e12029. https://doi.org/https://doi.org/10.1371/journal.pone.0012029
- Petti, S. (2009). Lifestyle risk factors for oral cancer. Oral Oncology, 45(4–5), 340–350. https://doi.org/https://doi.org/10.1016/j.oraloncology.2008.05.018
- Polamreddy, P., & Gattu, N. (2019). The drug repurposing landscape from 2012 to 2017: Evolution, challenges, and possible solutions. Drug Discovery Today, 24(3), 789–795. https://doi.org/https://doi.org/10.1016/j.drudis.2018.11.022
- Raghava, K. M., & Lakshmi, P. K. (2012). Overview of P-glycoprotein inhibitors: A rational outlook. Brazilian Journal of Pharmaceutical Sciences, 48(3), 353–367. https://doi.org/https://doi.org/10.1590/S1984-82502012000300002
- Rajib, S. A., & Siam, M. K. S. (2020). Characterization and analysis of mammalian AKR7A gene promoters: Implications for transcriptional regulation. Biochemical Genetics, 58(1), 171–188. https://doi.org/https://doi.org/10.1007/s10528-019-09936-y
- Rigsby, R. E., & Parker, A. B. (2016). Using the PyMOL application to reinforce visual understanding of protein structure. Biochemistry and Molecular Biology Education: A Bimonthly Publication of the International Union of Biochemistry and Molecular Biology, 44(5), 433–437. https://doi.org/https://doi.org/10.1002/bmb.20966
- Rosebush, M. S., Rao, S. K., Samant, S., Gu, W., Handorf, C. R., Pfeffer, L. M., & Nosrat, C. A. (2011). Oral cancer: Enduring characteristics and emerging trends. The Journal of the Tennessee Dental Association, 91(2), 28–29. https://www.ncbi.nlm.nih.gov/pubmed/21748976
- Roy, N. K., Monisha, J., Padmavathi, G., Lalhruaitluanga, H., Kumar, N. S., Singh, A. K., Bordoloi, D., Baruah, M. N., Ahmed, G. N., Longkumar, I., Arfuso, F., Kumar, A. P., & Kunnumakkara, A. B. (2019). Isoform-specific role of Akt in oral squamous cell carcinoma. Biomolecules, 9(7), 1–23. https://doi.org/https://doi.org/10.3390/biom9070253
- Schottel, B. L., Chifotides, H. T., & Dunbar, K. R. (2008). Anion-pi interactions. Chemical Society Reviews, 37(1), 68–83. https://doi.org/https://doi.org/10.1039/b614208g
- Scully, C., & Bagan, J. (2009). Oral squamous cell carcinoma overview. Oral Oncology, 45(4–5), 301–308. https://doi.org/https://doi.org/10.1016/j.oraloncology.2009.01.004
- Siam, M. K. S., Sayeem, M. M. S., Mohammed, M. K., & Rajib, S. A. (2012). In-silico experiment of the human CFTR sequence to identify common disease causing mutation and development of small drug therapies for cystic fibrosis. The 3D structure of the CFTR protein our tools. 20th Annual International Conference on Intelligent Systems for Molecular Biology. https://www.researchgate.net/publication/228332850_In-silico_experiment_of_the_human_CFTR_sequence_to_identify_common_disease_causing_mutation_and_development_of_small_drug_therapies_for_cystic_fibrosis
- Siam, M. K. S. (2020). In silico study of galuteolin and linarin against Akt1 and Akt2 proteins and investigation of CYP inhibitors against MAOB: Treatment for OSCC. https://doi.org/https://doi.org/10.1021/scimeetings.0c00012
- Siam, M. K. S., & Kabir, E. R. (2018). Functional analysis of iGlur Delta-2 and other depression associated proteins: Role of TRK, BDNF, CYP2B6, POLG, PICK1 for early detection and treatment of depression [Paper presentation]. Proceedings of the 9th International Conference on Computational Systems-Biology and Bioinformatics. https://doi.org/https://doi.org/10.1145/3291757.3291765
- Siam, M. K. S., Hossain, M. S., Kabir, E. R., & Rajib, S. A. (2017). In silico structure based designing of dihydrofolate reductase enzyme antagonists and potential small molecules that target DHFR protein to inhibit the folic acid biosynthetic pathways [Paper presentation]. The 8th International Conference on Computational Systems-Biology and Bioinformatics (CSBio 2017) (pp. 62–67). https://doi.org/https://doi.org/10.1145/3156346.3156358
- Siam, M. K. S., Shohan, M. U. S., & Zafroon, Z. (2020). Investigation of the anti-TB potential of selected alkaloid constituents using molecular docking approach. BioRxiv (pp. 1–15). https://doi.org/https://doi.org/10.1101/2020.04.28.067090
- Sudbo, J., & Reith, A. (2005). The evolution of predictive oncology and molecular-based therapy for oral cancer prevention. International Journal of Cancer, 115(3), 339–345. https://doi.org/https://doi.org/10.1002/ijc.20896
- Talarico, C., D'Antona, L., Scumaci, D., Barone, A., Gigliotti, F., Fiumara, C. V., Dattilo, V., Gallo, E., Visca, P., Ortuso, F., Abbruzzese, C., Botta, L., Schenone, S., Cuda, G., Alcaro, S., Bianco, C., Lavia, P., Paggi, M. G., Perrotti, N., & Amato, R. (2015). Preclinical model in HCC: The SGK1 kinase inhibitor SI113 blocks tumor progression in vitro and in vivo and synergizes with radiotherapy. Oncotarget, 6(35), 37511–37525. https://doi.org/https://doi.org/10.18632/oncotarget.5527
- Tandon, P., Dadhich, A., Saluja, H., Bawane, S., & Sachdeva, S. (2017). The prevalence of squamous cell carcinoma in different sites of oral cavity at our Rural Health Care Centre in Loni, Maharashtra - A retrospective 10-year study. Contemporary Oncology (Poznan, Poland), 21(2), 178–183. https://doi.org/https://doi.org/10.5114/wo.2017.68628
- Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet-Tieulent, J., & Jemal, A. (2015). Global Cancer Statistics, 2012. CA: A Cancer Journal for Clinicians, 65(2), 87–108. https://doi.org/https://doi.org/10.3322/caac.21262
- Trott, O., & Olson, A. J. (2010). Software news and update AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry, 31(2), 455–461. https://doi.org/https://doi.org/10.1002/jcc.21334
- Wang, S., Yang, Q., Fung, K. M., & Lin, H. K. (2008). AKR1C2 and AKR1C3 mediated prostaglandin D2 metabolism augments the PI3K/Akt proliferative signaling pathway in human prostate cancer cells. Molecular and Cellular Endocrinology, 289(1–2), 60–66. https://doi.org/https://doi.org/10.1016/j.mce.2008.04.004
- Wiederstein, M., & Sippl, M. J. (2007). ProSA-web: Interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Research, 35(Web Server issue), W407–W410. https://doi.org/https://doi.org/10.1093/nar/gkm290
- Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., Assempour, N., Iynkkaran, I., Liu, Y., Maciejewski, A., Gale, N., Wilson, A., Chin, L., Cummings, R., Le, D., … Wilson, M. (2018). DrugBank 5.0: A major update to the DrugBank database for 2018. Nucleic Acids Research, 46(D1), D1074–D1082. https://doi.org/https://doi.org/10.1093/nar/gkx1037
- Yang, H., Lou, C., Sun, L., Li, J., Cai, Y., Wang, Z., Li, W., Liu, G., & Tang, Y. (2019). AdmetSAR 2.0: Web-service for prediction and optimization of chemical ADMET properties. Bioinformatics (Oxford, England), 35(6), 1067–1069. https://doi.org/https://doi.org/10.1093/bioinformatics/bty707
- Zagorac, D., Jakovcevic, D., Gebremedhin, D., & Harder, D. R. (2008). Antiangiogenic effect of inhibitors of cytochrome P450 on rats with glioblastoma multiforme. Journal of Cerebral Blood Flow and Metabolism: Official Journal of the International Society of Cerebral Blood Flow and Metabolism, 28(8), 1431–1439. https://doi.org/https://doi.org/10.1038/jcbfm.2008.31